Global Neuropathic Pain Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Neuropathic Pain Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global Neuropathic Pain market finds that the global Neuropathic Pain market reached a value of USD 9263.0 million in 2022. It’s expected that the market will achieve USD 12324.0 million by 2028, exhibiting a CAGR of 4.87% during the forecast period.

Limitations

In recent years, there has been almost no difference between firstline and second-line therapies for the treatment of NP. Most recommendations for first-line and second-line treatment are based on antidepressants and anti-epileptic drugs. The clinical situation of neuropathic pain is complex, the etiology and pathophysiology are different, so the advantage of neuropathic pain is difficult to judge and treat. At present, the best means for treating neuropathic pain and its pathological conditions is still not recognized. This may include reasons for the relatively late understanding of neuropathic pain itself, and it is difficult to establish clear diagnostic criteria; there is a lack of well-designed large-scale clinical trials to evaluate the effectiveness of drugs for the treatment of neuropathic pain. Due to the lack of systematic treatment of neuropathic pain, treatment strategies are generally based on inaccurate evidence and very few clinical trials. The research process is relatively slow, and the cost of research is high. The drug approval process is long, which will result in market development. Certainly affected.

Region Overview:

From 2023-2028, United States is estimated to witness robust growth prospects.

Company Overview:

The top three companies are Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson Services Inc. with the revenue market share of 50.87%, 4.70%, 4.23% in 2018.

Pfizer is the world's largest research-based pharmaceutical company. The company operates three business units: healthcare, animal health and consumer care. The company's biggest source of income is prescription drugs. Pfizer's large drugs include the antidepressant Zoloft and the lipid-lowering drug Lipitor, the world's best-selling drug. Pfizer's products are sold in more than 150 countries.

Lilly was founded in 1876. Eli Lilly is committed to developing high quality medicines that meet actual needs. Provide products and services to 125 countries around the world.

Segmentation Overview:

Among different product types, Peripheral Neuropathy segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Hospitals segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Neuropathic Pain market covered in Chapter 3:

Abbott Laboratories
Eli Lilly and Company
Arbor Pharmaceuticals
Johnson & Johnson Services Inc.
Endo
Pfizer, Inc.
Novartis AG
Grunenthal Group

In Chapter 4 and Chapter 14.2, on the basis of types, the Neuropathic Pain market from 2018 to 2029 is primarily split into:

Peripheral Neuropathy
Entrapment Neuropathy
Phantom Limb Pain
Trigeminal Neuralgia
Post Herpetic Neuralgia (PHN)
Post Traumatic Neuropathy
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Neuropathic Pain market from 2018 to 2029 covers:

Hospitals
Clinics
Research Organizations

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)